Información del artículo
El Texto completo está disponible en PDF
Referencias Bibliográficas
[1.]
US Department of Health and Human Services (1989). Reducing the health consequences of smoking: 25 years of progress, a report of the Surgeon General, DHS Publication (CDC), Nº 89-8411 (Rockville MD. Department of Health and Human Services).
[2.]
World Health Organization.
Third action plan for a tobacco-free Europe 1997-2001, WHO, (1997),
[3.]
Peto R, López AD, Boreham J, et al, eds. Mortality from smoking in developed countries 1950-2000. Oxford University.
[4.]
American Psychiatric Association.
Diagnostic and Statistical Manual of Mental Disorders, Fourth, American Psychiatric Association, (1994),
[5.]
Henningfield JE, Schuh LM, Marvik ME. Pathophisiology of Tobacco Dependence. Eds. Phycopharmacology: The fourth generation of progress. New York: Raven Press 1.
[6.]
Russell MAH (1988). The role of blood nicotine levels, their rate of change and nicotine tolerance. In: Pomerlau OF and Pomerlau CS, eds: Nicotine replacement a cortical evaluation. pp 187-217 (NY AR Lirs Inc).
[7.]
Pomerlau OF.
Nicotine and the central nervous system: Biobihaivioural effects of cigarrete smoking.
Am J Med, 93 (1992), pp. 25-75
[8.]
Benowitz NL.
Pharmacological aspects of cigarette smoking and nicotine addiction.
New Eng J Med, 319 (1988), pp. 1318-1330
[9.]
Huges JR.
Symptons of tobacco withdrawal: a replication and extension.
Arch Gen Psychiatry, 48 (1991), pp. 52-59
[10.]
Henningfield J.E., Schuh L.M., et al.
Withdrawal: nicotine (Tobacco).
Enciclopedia of drugs and alcohol, pp. 1282-1286
[11.]
West R, Hajek P, Belcher M.
Time courseof cigarette withdrawal symptons while using nicotine gum.
Psychopharmacology,, 99 (1989), pp. 143-145
[12.]
Fagerstrom KO, Scheneider NG.
Mesuring nicotine dependence: a review of Fagestrom Tolerance Questionaire.
Journal of Behavioral Medecine, 12 (1989), pp. 159-182
[13.]
Fagerstrom KO. Efficacy of nicotine chewing. A review, in Pomerlau OF and Pomerlau CS eds: Nicotine replacement a cortical evaluation, 1998: 187-217. New York AR Liss Inc.
[14.]
Kenford S.L., Fiore M.C., et al.
Predicting smoking cessation; who will quit with and without the nicotine patch.
JAMA, 27 (1994), pp. 589-594
[15.]
Marín D., Salvador T..
Intervención mínima en el tabaquismo desde la Atención Primaria de Salud, Monografías Clínicas en Atención Primaria, Nº 2, (1989),
[16.]
Prochaska J.O., Di Clemente C.C..
Towards a comprehensive model of change.
Treating Addictive Behaviours: Processes of change, pp. 3-27
[17.]
Lekuona J., Anitua C..
Evolución del Tabaquismo en la CAV desde 1986 a 1997.
Osasunkaria, julio, 17 (1999), pp. 2-10
[18.]
Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A..
Prevalence of smoking among psychiatric outpatients.
Am J Psichiatry, 143 (1986), pp. 993-997
[19.]
Mortality in relation to smoking: Ten years observations of British Doctors.
Br Med J, 1 (1964), pp. 1399-1460
[20.]
Silagy C., Mant D., Fowler G., Lancaster T..
Nicotine replacement therapy for smoking cessation. Cochrane review, in: The Cochrane Library, 1, 2000, Update Software, (1999),
[21.]
Becoña E..
El tratamiento de fumadores por medio del chicle de nicotina.
Una revisión. Revista de Anālisis del Comportamiento,, 3 (1987), pp. 175-187
[22.]
Russell M.A.H., Jarvis M..
Theorical background and clinical use of nicotine chewing-gum in: Pharmacological adjuncts in smoking cessation.
Bethesda Med National Institute of Drug Abuse,, 53 (1985), pp. 110-130
[23.]
Herrera N, Franco R, Herrera L. Nicotine Gum, 2 and 4 mgr, for Nicotine Dependence. Chest, 1995, august, 2:108.
[24.]
Christen AG, Macdonal JL. Safety of nicotine-containing gum; in: Pomerleau OF and Pomerleau CS (eds). Nicotine Replacement: a critical evaluation, pp: 219-285. New York, AR Liss Inc.
[25.]
Transdermal Nicotine Study Group.
Transdermal nicotine for smoking cessation.
JAMA, 266 (1991), pp. 3133-3138
[26.]
Tonnesen P., Norregard J., Simonsen K., et al.
A double blind trial of a 16-hour transdermal nicotine patch in smoking cessation.
N Engl J Med., 325 (1991), pp. 311-315
[27.]
Imperial Cancer Research Fund General Practice Research Group.
Effectiveness of anicotine patch in helping people stop smoking: results of a randomised trial in general practice.
BMJ, 306 (1993), pp. 1304-1308
[28.]
Bircher A.J., Howald H., Rufli T..
Adverse skin reactions to nicotine in a transdermal therapeutic system.
Contact Dermatitis, 25 (1991), pp. 230-236
[29.]
Greenland S., Satterfield M.H., Lanes S.F..
A meta-analysis to asses the incidence of adverse effects associated with the transdermal nicotine patch.
Drug Safety, 18 (1998), pp. 297-308
[30.]
Kornitzer M., Boutsen M., Dramaix M., et al.
Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial.
Prev Med., 24 (1995), pp. 41-47
[31.]
Jonathan Foulds.
The relationship between tobacco use and mental disorders.
Current Opinion in Psychiatry, 12 (1999), pp. 303-306
[32.]
Nicorette Nasal Spray Monograph, ADIS, (1993),
[33.]
Sutherland G., Stapleton J.A., Russell M.A., et al.
Randomised controlled trial of nasal nicotine spray in smoking cessation.
Lancet, 340 (1992), pp. 324-329
[34.]
Blondal T., Gudmunsson L.J., Olafsdottir I., Gustavsson G., Westin A..
Nicotine nasal spray, with nicotine patch for smoking cessation: randomised trial with six year follow up.
BMJ, 318 (1999), pp. 285-289
[35.]
Tonnesen P., Norregard J., et al.
A double-blind trial of a nicotine inhaler for smoking cessation.
JAMA, 269 (1993), pp. 1268-1271
[36.]
Henningfield J.E..
Nicotine Medications for smoking cessation.
N Eng J Med., 333 (1995), pp. 1196-1203
[37.]
Edwards N.B., Murphy J.K., Downs A.D., Alkerman B.J., Rosenthal T.L..
Doxepins as an adjunct to smoking cessation: a double-blind pilot study.
Am J Psychiatry, 146 (1989), pp. 373-376
[38.]
Ascher J.A., Cole J.O., Feighner J.P., Ferris R.M., et al.
Bupropión: a review of its mechanism of antidepressant activity.
J Clin Psychiatry,, 56 (1995), pp. 395-401
[39.]
Hurt R.D., Sachs D.P., Glover E.D., et al.
A comparison of sustrained-release bupropion and placebo for smoking cessation.
N Eng J Med., 337 (1997), pp. 1195-1202
[40.]
Jorenby D.E., Leischow S.J., Nides M.A., et al.
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
N Eng J Med., 340 (1999), pp. 685-691
[41.]
Hilleman D.E., Mohiuddin S.M., Del Core M.G..
Effect of buspiron on withdrawal symptoms associated with smoking cessation.
Arch Intern Med, 152 (1992), pp. 350-352
[42.]
West R., Hajek P., McNeill A..
Effect of buspirone on cigarette withdrawal symtoms and short-term abstinence rates in a smokers clinic.
Psychopharmacology,, 104 (1991), pp. 91-96
[43.]
Covey LS, Glassman AH. A Meta-Analysis of Double-blind Placebo-controlled Trials of clonidine for Smoking Cessation. British Journal of Addiction, 86:991-998.
[44.]
Glassman A.H., Stetner F., Walsh T., et al.
Heavy smokers, smoking cessation, and clonidine.
JAMA., 259 (1988), pp. 2863-2866
[45.]
Ashton H., Stepney R..
Smoking, psychologyand pharmacology, Tavistock Publications, (1983),
[46.]
Lando H.A..
Aversive conditioning and contingency management in the treatment of smoking.
J Consult Clin Psychol, 44 (1976), pp. 312
[47.]
Morrow R., Nepps P., McIntosh M..
Silver acetate mouth spray as an aid in smoking cessation: results of a double-blind trial.
J Am Board Fam Pract, 6 (1993), pp. 353-357
[48.]
Malcom R., Currey H.S., et al.
Silver acetate gum as a deterrent to smoking.
Chest, 90 (1986), pp. 107-111
[49.]
Stone LA, Torchiana ML, et al. Ganglionic blocking properties of mecamylamine a secondary amine. J Pharmacol Exp Ther 117;169-183
[50.]
Behm F.M., Schur C., Levin E.D., et al.
Clinical evaluation of a citric acid inhaler for smoking cessation.
Drug-Alcohol Depend, 31 (1993), pp. 131-138
[51.]
Schectman G..
Estimating ascorbic acid requirements for cigarette smokers.
Ann NY Acad Sci, 686 (1993), pp. 335-345
[52.]
Bridges A.B., Scott N.A., et al.
Age, sex, cigarette smoking and indices of free radical activity in healthy humans.
Eur J Med, 2 (1993), pp. 205-208
[53.]
Jeffery P.K., Rogers D.F., Ayers M.M..
Effectsof oral acetylcysteine on tobacco smoke induced secretory cell hyperplasia.
Eur J Resp Dis, 66 (1985), pp. 117-122
[54.]
Krishnan-Sarin S., Rosen M.I., O'Malley S..
Naloxone challenge in smokers.
Arch Gen Psychiatry, 56 (1999), pp. 663-668
Copyright © 2000. Academia de Ciencias Médicas de Bilbao